PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharming Group N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026
$9.11−0.25 (-2.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2277.5
- Dividend yield
- –
Pharming statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Pharming | Industry median |
|---|---|---|
| Market Cap | $6.39B | $197.05M |
| Enterprise Value | $6.25B | $106.56M |
| PE Ratio | 2277.50 | 20.52 |
| PS Ratio | 16.99 | 3.93 |
| P/FCF Ratio | 118.47 | 18.25 |
| P/OCF Ratio | 116.84 | 13.78 |
Enterprise value
| Measure | Pharming | Industry median |
|---|---|---|
| EV / Sales | 16.61 | 2.69 |
| EV / EBITDA | 241.74 | 14.86 |
| EV / EBIT | 241.74 | 19.00 |
| EV / FCF | 115.77 | 21.02 |
Income (trailing twelve months)
| Measure | Pharming | Industry median |
|---|---|---|
| Revenue | $376.13M | $57.94M |
| Gross Profit | $330.63M | $90.47M |
| Operating Income | $25.84M | -$21.44M |
| Pretax Income | $12.85M | -$14.45M |
| Net Income | $2.85M | -$22.46M |
| EBITDA | $25.84M | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | Pharming | Industry median |
|---|---|---|
| Gross Margin | 87.9% | 52.3% |
| Operating Margin | 6.87% | -44.5% |
| Pretax Margin | 3.42% | -13.0% |
| Profit Margin | 0.76% | -39.2% |
| EBITDA Margin | 6.87% | -31.3% |
| FCF Margin | 14.3% | -8.85% |
Returns
| Measure | Pharming | Industry median |
|---|---|---|
| Return on Assets (ROA) | 0.63% | -41.0% |
| Return on Capital Employed (ROCE) | 6.73% | -37.8% |
Growth
| Measure | Pharming | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 26.6% | 6.01% |
| Revenue Growth (3Y CAGR) | 22.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 12.1% | 6.42% |
| EPS Growth (3Y CAGR) | -40.5% | -0.17% |
| EPS Growth (5Y CAGR) | -40.8% | 3.77% |
Balance sheet
| Measure | Pharming | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $145.31M | $62.42M |
| Net Cash (Debt) | $145.31M | $15.68M |
| Net Cash Per Share | $0.21 | $0.65 |
| Working Capital | $183.68M | $75.77M |
Financial position
| Measure | Pharming | Industry median |
|---|---|---|
| Current Ratio | 2.59 | 3.30 |
| Quick Ratio | 1.73 | 2.39 |
| Interest Coverage | 131.85 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Pharming | Industry median |
|---|---|---|
| Operating Cash Flow | $54.71M | -$12.35M |
| Capital Expenditures | -$749.00K | -$1.06M |
| Free Cash Flow | $53.96M | -$20.28M |
| FCF Per Share | $0.08 | -$0.41 |
Efficiency
| Measure | Pharming | Industry median |
|---|---|---|
| Asset Turnover | 0.84 | 0.38 |
| Inventory Turnover | 0.75 | 2.67 |
| Revenue Per Employee | $7.52K | $398.96K |
| Profits Per Employee | $57 | -$732.08K |
| Employee Count | 50,000 | 73 |
Dividends and yields
| Measure | Pharming | Industry median |
|---|---|---|
| Earnings Yield | 0.04% | -21.2% |
| FCF Yield | 0.84% | -7.64% |
Shares
| Measure | Pharming | Industry median |
|---|---|---|
| Shares Outstanding | 701,680,000 | 59,128,900 |
| Shares Change (YoY) | -4.91% | 11.1% |
| Float | 701,680,000 | 48,744,500 |
| Shares Held by Insiders | 0.00% | 11.8% |
| Shares Held by Institutions | 0.32% | 59.4% |
Taxes
| Measure | Pharming | Industry median |
|---|---|---|
| Income Tax | $10.31M | $91.50K |
| Effective Tax Rate | 80.3% | 20.6% |
Scores
| Measure | Pharming | Industry median |
|---|---|---|
| Altman Z-Score | 17.81 | 0.10 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Pharming's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.